Clinical trials: Multiple Sclerosis, Primary Progressive
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NACPMS (NCT05122559)
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Emmanuelle Waubant, MD PhD
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- FENtrepid (NCT04544449)
- Testing
- Fenebrutinib, Ocrelizumab
- Where
- 190 sites in United States, Argentina and 26 more
- Volunteers
- 985 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with Multiple Sclerosis.
- Trial name
- STEM (NCT03983681)
- Testing
- Strategy-Based Training to Enhance Memory (STEM)
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kessler Foundation
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
This study aims to: analyze prospectively the prevalence of subclinical oculomotor disorders (OMDs) in different phenotypes of Multiple Sclerosis (MS) and to study correlations with brain MRI T2 data.
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis (MS) Relapsing Remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- EYE-SEP (NCT04705610)
- Testing
- Video-oculography / Social cognition tasks / Neuropsychological evaluations
- Where
- Monaco
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis, Progressive
Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis
In this clinical trial, researchers are exploring a novel approach to delivering therapy directly into the spinal fluid, which surrounds and nourishes the brain and spinal cord.
- Trial name
- NCT06841068
- Testing
- Amniotic fluid or placental CD117 stem cells
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Libyan Multiple Sclerosis Registry Study
This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya.
- Trial name
- NCT07264725
- Testing
- Disease-Modifying Therapies
- Where
- Libya
- Volunteers
- 369 people
- Sponsor
- University of Zintan
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Primary Progressive Multiple Sclerosis
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks.
- Trial name
- NCT03362294
- Testing
- GA Depot 40mg once monthly, GA Depot 25mg once monthly
- Where
- 7 sites in Israel, Moldova
- Volunteers
- 30 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant.
- Trial name
- NCT04550650
- Testing
- Training groupe, PNF, Spinning grp
- Where
- Hungary
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital